Sanofi India Q4 PAT up 26.4% at Rs123cr on lower material costs and exceptional gains


Sanofi India reported -12.83% fall in total revenues for the Dec-20 quarter on consolidated basis at Rs720.30cr. Although the company does operate in the relatively stable business of pharmaceuticals, the impact of the COVID pandemic, social distancing and the lockdowns was felt.

While sales have recovered from the lows of Jun-20 and Sep-290 quarter, they are still some way away from the pre-COVID levels of sales. The company has declared a dividend of Rs.365/share including a special dividend of Rs.240 crore.

The consolidated Profit after tax (PAT) for the Dec-20 quarter was up 26.41% at Rs123cr. Three factors worked favourably for-profit growth in the quarter. Firstly, the cost of raw materials fell sharply in the quarter. Exceptional gains in the current quarter from the slump sale of the Ankleshwar plan to Zentiva also improved profits.

Lastly, the tax liability was also much lower in the quarter and they all combined to boost profits. As a result, the PAT margins improved very sharply from 11.78% in Dec-19 to 17.08% in Dec-20 quarter.

Financial highlights for Dec-20 compared yoy and sequentially

Sanofi India

Rs in Crore






Total Income (Rs cr)

₹ 720.30

₹ 826.30


₹ 686.60


Net Profit (Rs cr)

₹ 123.00

₹ 97.30


₹ 132.90


Diluted EPS (Rs)

₹ 53.41

₹ 42.26

₹ 57.71

Net Margins





Related Story

Related Tags:

$('#popup_mobile_reg').keypress(function (e) { var mobileNumber = $("#popup_mobile_reg").val(); var regex = new RegExp("^[0-9]+$"); var str = String.fromCharCode(!e.charCode ? e.which : e.charCode); if (regex.test(str)) { if (mobileNumber.length

#Sanofi #India #PAT #Rs123cr #material #costs #exceptional #gains

( With inputs from indiainfoline)